MX2022015847A - Proteinas de union a cd123 y composiciones y metodos relacionados. - Google Patents
Proteinas de union a cd123 y composiciones y metodos relacionados.Info
- Publication number
- MX2022015847A MX2022015847A MX2022015847A MX2022015847A MX2022015847A MX 2022015847 A MX2022015847 A MX 2022015847A MX 2022015847 A MX2022015847 A MX 2022015847A MX 2022015847 A MX2022015847 A MX 2022015847A MX 2022015847 A MX2022015847 A MX 2022015847A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- methods
- binding
- binding proteins
- binding domain
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 abstract 5
- 230000027455 binding Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 102000052088 human IL3RA Human genes 0.000 abstract 1
- 230000009149 molecular binding Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente descripción hace referencia a moléculas de proteína que se unen específicamente a CD123, que pueden tener al menos un dominio de unión a CD123 humanizado o humano. Dichas moléculas son útiles para el tratamiento del cáncer. La molécula de proteína que se une a CD123 puede tener un segundo dominio de unión que se une a otro objetivo. En una modalidad, las moléculas de polipéptido multiespecífico se unen tanto a células que expresan CD123 como al complejo receptor de células T de las células T para inducir la citotoxicidad, activación y proliferación de células T dependiente del objetivo. La descripción proporciona también composiciones farmacéuticas que comprenden las moléculas de polipéptido de unión a CD123, moléculas de ácido nucleico que codifican estos polipéptidos y métodos para confeccionar estas moléculas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662397736P | 2016-09-21 | 2016-09-21 | |
US201762466192P | 2017-03-02 | 2017-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015847A true MX2022015847A (es) | 2023-01-24 |
Family
ID=61690646
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003225A MX2019003225A (es) | 2016-09-21 | 2017-09-21 | Proteínas de unión a cd123 y composiciones y métodos relacionados. |
MX2022015847A MX2022015847A (es) | 2016-09-21 | 2019-03-20 | Proteinas de union a cd123 y composiciones y metodos relacionados. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003225A MX2019003225A (es) | 2016-09-21 | 2017-09-21 | Proteínas de unión a cd123 y composiciones y métodos relacionados. |
Country Status (17)
Country | Link |
---|---|
US (3) | US11242400B2 (es) |
EP (1) | EP3515491A4 (es) |
JP (2) | JP7224289B2 (es) |
KR (1) | KR102559732B1 (es) |
CN (1) | CN109952112A (es) |
AU (1) | AU2017331256A1 (es) |
BR (1) | BR112019005333A2 (es) |
CA (1) | CA3037688A1 (es) |
CO (1) | CO2019003951A2 (es) |
IL (1) | IL265484A (es) |
MX (2) | MX2019003225A (es) |
MY (1) | MY194290A (es) |
PH (1) | PH12019500609A1 (es) |
SG (1) | SG10202102846SA (es) |
UA (1) | UA127450C2 (es) |
WO (1) | WO2018057802A1 (es) |
ZA (1) | ZA201902323B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES |
WO2020227071A1 (en) * | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
CN110804096B (zh) * | 2019-11-21 | 2021-07-06 | 深圳普瑞金生物药业有限公司 | Cd123单域抗体、核苷酸序列、表达载体及试剂盒 |
MX2022008654A (es) * | 2020-01-13 | 2022-08-18 | Aptevo Res & Development Llc | Formulaciones para productos terapeuticos proteicos. |
JP2023512446A (ja) * | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
CN111349163A (zh) | 2020-02-05 | 2020-06-30 | 北京智仁美博生物科技有限公司 | 针对cd123的单克隆抗体 |
CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
EP4232159A1 (en) * | 2020-10-23 | 2023-08-30 | Icahn School of Medicine at Mount Sinai | Sars-cov-2 antibodies and uses thereof |
MX2023006426A (es) * | 2020-12-01 | 2023-07-17 | Aptevo Res & Development Llc | Antígenos asociados a tumores y proteínas de unión a cd3 y composiciones y métodos relacionados. |
KR20240024819A (ko) * | 2021-05-21 | 2024-02-26 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 단백질 치료제의 투약 요법 |
CN117660325B (zh) * | 2024-01-31 | 2024-04-19 | 苏州科为康生物医药科技有限公司 | 一种制备脐带血msc的培养基及其方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
AU2002329647A1 (en) | 2001-07-26 | 2003-02-24 | University Of Utah Research Foundation | In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation |
HUE048922T2 (hu) * | 2002-05-22 | 2020-09-28 | Novartis Ag | Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra |
EP1641827A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
EP1711527A4 (en) * | 2003-12-15 | 2008-09-03 | Dendreon Corp | HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS |
US8551920B2 (en) | 2005-02-01 | 2013-10-08 | Morpho Sys AG | Libraries and methods for isolating antibodies |
EP1885860A2 (en) * | 2005-05-16 | 2008-02-13 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
SG10201504917PA (en) | 2005-07-11 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
US7949480B2 (en) | 2006-06-14 | 2011-05-24 | Simphotek, Inc. | Method for determining an interaction between an electromagnetic radiation and a material |
SI2066694T1 (sl) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za diagnosticiranje in zdravljenje raka |
WO2009017823A2 (en) | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
NZ591134A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa) |
CA2764432C (en) * | 2009-04-27 | 2017-10-24 | Kyowa Hakko Kirin Co., Ltd. | Interleukin-3 receptor alpha chain-binding antibody to treat leukemia |
PL2477648T3 (pl) | 2009-09-15 | 2022-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
CA2870545A1 (en) * | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Cd3 binding polypeptides |
ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
RS60305B1 (sr) * | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
EP4039710A3 (en) * | 2015-01-23 | 2022-10-19 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
CA2976360A1 (en) * | 2015-02-11 | 2016-08-18 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
WO2017053469A2 (en) * | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
US20170349660A1 (en) | 2016-06-01 | 2017-12-07 | Xencor. Inc. | Bispecific antibodies that bind cd123 and cd3 |
EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES |
-
2017
- 2017-09-21 EP EP17853936.7A patent/EP3515491A4/en active Pending
- 2017-09-21 CA CA3037688A patent/CA3037688A1/en active Pending
- 2017-09-21 BR BR112019005333A patent/BR112019005333A2/pt unknown
- 2017-09-21 WO PCT/US2017/052808 patent/WO2018057802A1/en unknown
- 2017-09-21 KR KR1020197011271A patent/KR102559732B1/ko active IP Right Grant
- 2017-09-21 SG SG10202102846SA patent/SG10202102846SA/en unknown
- 2017-09-21 JP JP2019537049A patent/JP7224289B2/ja active Active
- 2017-09-21 AU AU2017331256A patent/AU2017331256A1/en active Pending
- 2017-09-21 UA UAA201904226A patent/UA127450C2/uk unknown
- 2017-09-21 MY MYPI2019001301A patent/MY194290A/en unknown
- 2017-09-21 MX MX2019003225A patent/MX2019003225A/es unknown
- 2017-09-21 US US16/335,561 patent/US11242400B2/en active Active
- 2017-09-21 CN CN201780069428.3A patent/CN109952112A/zh active Pending
-
2018
- 2018-03-22 US US15/933,324 patent/US10676533B2/en active Active
-
2019
- 2019-03-19 IL IL265484A patent/IL265484A/en unknown
- 2019-03-20 PH PH12019500609A patent/PH12019500609A1/en unknown
- 2019-03-20 MX MX2022015847A patent/MX2022015847A/es unknown
- 2019-04-12 ZA ZA2019/02323A patent/ZA201902323B/en unknown
- 2019-04-19 CO CONC2019/0003951A patent/CO2019003951A2/es unknown
-
2021
- 2021-12-21 US US17/557,440 patent/US11939392B2/en active Active
-
2023
- 2023-02-07 JP JP2023016697A patent/JP2023058573A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MY194290A (en) | 2022-11-26 |
US20200165346A1 (en) | 2020-05-28 |
US20190071513A1 (en) | 2019-03-07 |
CN109952112A (zh) | 2019-06-28 |
KR102559732B1 (ko) | 2023-07-26 |
SG10202102846SA (en) | 2021-04-29 |
AU2017331256A1 (en) | 2019-04-04 |
UA127450C2 (uk) | 2023-08-30 |
MX2019003225A (es) | 2019-06-10 |
US10676533B2 (en) | 2020-06-09 |
US11242400B2 (en) | 2022-02-08 |
JP2023058573A (ja) | 2023-04-25 |
PH12019500609A1 (en) | 2019-06-03 |
JP7224289B2 (ja) | 2023-02-17 |
US20220363773A1 (en) | 2022-11-17 |
US11939392B2 (en) | 2024-03-26 |
EP3515491A4 (en) | 2020-09-16 |
CA3037688A1 (en) | 2018-03-29 |
CO2019003951A2 (es) | 2019-04-30 |
ZA201902323B (en) | 2023-07-26 |
EP3515491A1 (en) | 2019-07-31 |
WO2018057802A1 (en) | 2018-03-29 |
BR112019005333A2 (pt) | 2019-06-11 |
KR20190069437A (ko) | 2019-06-19 |
IL265484A (en) | 2019-05-30 |
JP2019531764A (ja) | 2019-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500609A1 (en) | Cd123 binding proteins and related compositions and methods | |
PH12018500520A1 (en) | Cd3 binding polypeptides | |
WO2016094873A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods | |
PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
AR105444A1 (es) | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) | |
PH12017500892A1 (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
WO2016130819A3 (en) | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins | |
MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
MX2019008536A (es) | Aglutinantes de albumina serica mejorados. | |
EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
MX2017001263A (es) | Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer. | |
EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
NZ759601A (en) | Aggrecan binding immunoglobulins | |
WO2017089780A3 (en) | Peptides | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
EP3974443A3 (en) | Peptides derived from melanoma-associated antigen b2 (mageb2) | |
EA201990773A1 (ru) | Cd123-связывающие белки и относящиеся к ним композиции и способы | |
AU2018278809A1 (en) | Recombinant ROBO2 proteins, compositions, methods and uses thereof | |
WO2017089781A3 (en) | Peptides derived from abnormal spindle-like microcephaly-associated protein (aspm) and complexes comprising such peptides bound to mhc molecules | |
WO2016040767A3 (en) | Chrdl-1 epitopes and antibodies | |
EA201991139A1 (ru) | Новые т-клеточные рецепторы и иммунотерапия с их применением | |
EA201990488A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением |